Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

被引：0

作者：

Rodney J Scott

机构：

[1] John Hunter Hospital,Discipline of Medical Genetics, Faculty of Health, University of Newcastle, Newcastle, NSW 2308, Australia; Centre for Information Based Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW 2305, Australia;

来源：

Breast Cancer Research | / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming.

引用

共 50 条

[1] Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
Scott, Rodney J.
BREAST CANCER RESEARCH, 2010, 12 (01)
[2] Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer
Leu, Jyh-Der
Wang, Chung-Yih
Tsai, Han-Yi
Lin, I-Feng
Chen, Ran-Chou
Lee, Yi-Jang
ONCOLOGY REPORTS, 2011, 25 (06) : 1755 - 1763
[3] Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients
Yadav, P.
Masroor, M.
Tanwer, K.
Mir, R.
Javid, J.
Ahmad, I.
Zuberi, M.
Kaza, R. C. M.
Jain, S. K.
Khurana, N.
Ray, P. C.
Saxena, A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (07): : 728 - 734
[4] Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer
Nunobiki, Osamu
Ueda, Masatsugu
Yamamoto, Michiko
Toji, Eisaku
Sato, Naomi
Izuma, Shinji
Okamoto, Yoshiaki
Torii, Kiyo
Noda, Sadamu
HUMAN CELL, 2009, 22 (04) : 101 - 106
[5] Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer
Osamu Nunobiki
Masatsugu Ueda
Michiko Yamamoto
Eisaku Toji
Naomi Sato
Shinji Izuma
Yoshiaki Okamoto
Kiyo Torii
Sadamu Noda
Human Cell, 2009, 22 : 101 - 106
[6] Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients
P. Yadav
M. Masroor
K. Tanwer
R. Mir
J. Javid
I. Ahmad
M. Zuberi
R. C. M. Kaza
S. K. Jain
N. Khurana
P. C. Ray
A. Saxena
Clinical and Translational Oncology, 2016, 18 : 728 - 734
[7] The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies
Cox, David G.
Deer, Dwayne
Guo, Qun
Tworoger, Shelley S.
Hankinson, Susan E.
Hunter, David J.
De Vivo, Immaculata
CANCER CAUSES & CONTROL, 2007, 18 (06) : 621 - 625
[8] Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
Marjanka K Schmidt
Johanna Tommiska
Annegien Broeks
Flora E van Leeuwen
Laura J Van't Veer
Paul DP Pharoah
Douglas F Easton
Mitul Shah
Manjeet Humphreys
Thilo Dörk
Scarlett A Reincke
Rainer Fagerholm
Carl Blomqvist
Heli Nevanlinna
Breast Cancer Research, 11
[9] Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
Schmidt, Marjanka K.
Tommiska, Johanna
Broeks, Annegien
van Leeuwen, Flora E.
Van't Veer, Laura J.
Pharoah, Paul D. P.
Easton, Douglas F.
Shah, Mitul
Humphreys, Manjeet
Dork, Thilo
Reincke, Scarlett A.
Fagerholm, Rainer
Blomqvist, Carl
Nevanlinna, Heli
BREAST CANCER RESEARCH, 2009, 11 (06):
[10] THE P53 ARG72PRO AND MDM2-309 POLYMORPHISMS AND RISK OF LIVER CANCER IN THE MOROCCAN PATIENTS
Ezzikouri, Sayeh
El Feydi, Abdellah Essaid
Akil, Abdellah
Afifi, Rajaa
ElKihal, Latifa
Benazzouz, Mustapho
Hassar, Mohammed
Pineau, Pascal
Benjelloun, Soumaya
HEPATOLOGY, 2008, 48 (04) : 1171A - 1171A

← 1 2 3 4 5 →